Walloon
VC Fund
Namur, Belgium
Walloon is a VC fund in Namur focused on Biotechnology and Health Care. Walloon provides financial services for startups.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 86%
Last updated:
For AI agents: llms.txt
Industries Walloon invests in
Stages Walloon invests in
Countries Walloon invests in
Investment Focus
Industry
- Biotechnology 9 (64%)
- Health Care 4 (29%)
- Therapeutics 2 (14%)
- Pharmaceutical 2 (14%)
- Farming 1 (7%)
Stage
- Grant 9 (64%)
- Series A 1 (7%)
Country
- Belgium 8 (57%)
- United States 1 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| GENFLOW is dedicated to the development and commercialization of novel therapeutics targeting aging in dogs and humans. | $396.5K / Grant / Mar 02, 2026 | ||
| GENFLOW is dedicated to the development and commercialization of novel therapeutics targeting aging in dogs and humans. | $4.6M / Grant / Jul 17, 2025 | ||
BiocSol
|
BiocSol focus on sustainable microbial-based crop protection. | Grant / Feb 03, 2025 | |
| GENFLOW is dedicated to the development and commercialization of novel therapeutics targeting aging in dogs and humans. | $413.1K / Grant / May 30, 2024 | ||
| Hyloris Pharmaceuticals is an innovative specialty pharmaceutical company focused on adding value to the healthcare system by reformulating well-known pharmaceuticals. Hyloris Pharmaceuticals develop innovative proprietary products that offer significant advantages compared to currently available alternatives. | $1.1M / Grant / Jun 08, 2023 | ||
| EsoBiotec is a Belgian biotechnology business focused on the discovery of novel cancer therapies.EsoBiotec's objective is to enable the human body to fight cancer by delivering 'in vivo' cell engineering to patients. | $3.5M / Grant / Sep 30, 2021 | ||
| EXO Biologics is a biotech company developing biopharmaceuticals using extracellular vesicles. | $4.5M / Grant / Feb 05, 2021 | ||
| ATB Therapeutics is a biopharmaceutical company that provides novel therapeutic solutions and treatments for cancer patients. | Grant / Dec 23, 2019 | ||
| Convert Pharmaceuticals is a clinical phase I-IIa drug development company, that is building a proprietary drug pipeline exploiting tumor microenvironment specific factors for therapeutic benefit. Convert’s lead product is a hypoxia activated prodrug (HAP). Hypoxia constitutes a therapeutic obstacle as it promotes the development of resistance toconventional anti-cancer treatments. Convert Pharmaceuticals combines proprietary insights in the tumor microenvironment with expertise in drug and biomarker development to develop effective and well-tolerated HAPs. | $14.9M / Series A / Feb 28, 2018 | ||
| Convert Pharmaceuticals is a clinical phase I-IIa drug development company, that is building a proprietary drug pipeline exploiting tumor microenvironment specific factors for therapeutic benefit. Convert’s lead product is a hypoxia activated prodrug (HAP). Hypoxia constitutes a therapeutic obstacle as it promotes the development of resistance toconventional anti-cancer treatments. Convert Pharmaceuticals combines proprietary insights in the tumor microenvironment with expertise in drug and biomarker development to develop effective and well-tolerated HAPs. | Grant / Feb 28, 2018 | ||
| See all 14 investments → | |||
Co-Investors
Eurostars
2 deals together
Droia Ventures
1 deal together
Meusinvest (Noshaq)
1 deal together
Spinventure
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Walloon invest in?
Walloon invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Grant and Series A stage. Most of the 14 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Walloon last invest?
The most recent investment recorded for Walloon closed in Mar 2026. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
